Novartis Sells India Stake for $159M to ChrysCapital-Led Group

Introduction

Swiss pharmaceutical major Novartis AG has announced its decision to exit its listed Indian entity, Novartis India Limited, by selling its entire 70.68% stake. The transaction, valued at approximately $159 million (₹1,446 crore), will see the ownership transfer to a consortium led by private equity firm ChrysCapital. This move marks a significant step in Novartis's global strategy to streamline its operations and focus on high-margin, innovative medicines, effectively drawing the curtain on its decades-long presence in India's public stock markets.

The Landmark Transaction

The deal involves the sale of 17.45 million shares held by the promoter, Novartis AG. The buyer is a consortium comprising WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners. According to exchange filings, the agreement was signed on February 19, 2026, formalizing the transfer of control. Upon completion, Novartis AG will cease to be the promoter of Novartis India Limited, and the ChrysCapital-led group will assume full control of the company's operations and strategic direction.

Mandatory Open Offer Details

As per India's takeover regulations, the acquisition of a controlling stake triggers a mandatory open offer to public shareholders. The consortium will make an open offer to acquire an additional 26% of Novartis India's shares from the public. The offer price has been set at ₹860.64 per share. If fully subscribed, this could potentially increase the consortium's total holding to approximately 96.7%, further consolidating their ownership. Axis Capital has been appointed to manage the open offer process.

Market Reacts Positively

Investors responded with strong optimism to the announcement. On the day following the news, shares of Novartis India surged, hitting the 20% upper circuit limit on the Bombay Stock Exchange (BSE). The stock price jumped from its previous close of ₹830.45 to a high of ₹996.5. This sharp rally reflects market confidence in the new ownership and the potential for strategic repositioning under private equity management. The deal values the company at a premium over its trading price before the announcement.

A Strategic Global Realignment

Novartis AG's decision to divest its stake is a direct result of a broader global restructuring initiated two years prior. The Swiss drugmaker is sharpening its focus on patented, high-value therapies in core areas like oncology, immunology, and neuroscience. The Indian subsidiary, which primarily deals in branded generics and mass-market drugs like the painkiller Voveran, no longer aligns with this innovation-led global strategy. Over the past decade, the Indian unit had already begun outsourcing manufacturing and discontinuing legacy brands, making it a profitable but low-growth asset attractive to a different class of investors.

The Buyer's Perspective

For ChrysCapital, this acquisition marks its first majority stake purchase in the Indian pharmaceutical sector, although it has a strong investment history in the space with stakes in companies like Intas Pharmaceuticals, Eris Lifesciences, and Corona Remedies. The private equity firm is acquiring a stable, profitable business with established brands in diabetes, cardiology, and dermatology. The new owners are expected to retain the company's listed status and reposition it to compete more effectively in India’s domestic formulations market.

Key Deal Metrics

What Remains of Novartis in India?

It is important to note that this transaction does not signify a complete exit for Novartis from India. The Swiss company will continue to operate through its unlisted, wholly-owned subsidiary, Novartis Healthcare Pvt Ltd. This entity is central to its strategic goals and includes its commercial arm for innovative medicines, the Novartis Corporate Center in Hyderabad, and robust R&D teams. Novartis Healthcare conducts clinical trials at over 300 sites across India and employs more than 9,000 associates, remaining a key part of the company's global operations.

Future of Novartis India Limited

The path forward for Novartis India involves several key steps. The transaction is subject to customary regulatory and corporate approvals, with the closing expected in the third quarter of 2026. Following the transfer of control, the company will be required to change its name within 120 days to remove any association with the Novartis brand, signaling a complete separation. The new management will then steer the company's future growth in the Indian market.

Conclusion

The sale of Novartis AG's stake in its Indian listed arm is a strategic pivot that aligns with its global focus on innovation while unlocking value from its legacy assets. For ChrysCapital, it presents an opportunity to take control of a well-established pharmaceutical business and drive its next phase of growth. This deal also reflects a broader trend of multinational corporations re-evaluating the structure of their operations in emerging markets, often choosing to separate their global innovation hubs from local commercial entities.